Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Omnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B)

NCT: NCT07317102 · RECRUITING

NCT IDNCT07317102
StatusRECRUITING
Start Date2026-03-16
Completion2027-11

Brief Summary

The purpose of this postmarket clinical investigation is to evaluate the levels of glycemic control, quality of life, and satisfaction, as well as the patient experience, and acute diabetes complication rates provided by the Omnipod 5 Automated Insulin Delivery System (referred to as the Omnipod 5 System) in a real-world setting.

Frequently Asked Questions

What is Omnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B)?

Omnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B) is a clinical trial registered under NCT07317102. Current status: RECRUITING.

What is the status of NCT07317102?

The current status of NCT07317102 (Omnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B)) is: RECRUITING.

When did Omnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B) start?

Omnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B) started on 2026-03-16.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑